iVascular has revealed the three-year follow-up results from the LUMIFOLLOW registry, a large real-world study evaluating the safety and efficacy of the Luminor drug-coated balloon (DCB) in the treatment of femoropopliteal artery disease. The data was presented by Eric Ducasse, (Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France), principal investigator of the study, at the 2026 Leipzig Interventional Course (27–30 January, Leipzig, Germany).
LUMIFOLLOW is a multicentre, real-world registry including 542 patients from 15 centres in France. The study reflects routine clinical practice and includes a broad spectrum of lesion complexity. Notably, 43.6% of lesions were classified as TASC C and D, and 24.2% of treated cases were restenotic lesions, underlining the challenging nature of the population evaluated.
At three years, 87.3% of patients remained free from revascularisation, confirming durable treatment effect, states the company. No device-related safety concerns were reported during the follow-up period.
These results reinforce Luminor’s differentiation in long-term vessel patency and clinical durability, even in complex and high-risk femoropopliteal lesions.
“In the LUMIFOLLOW study we are able to conclude Luminor’s efficacy and safety in a real-life population,” commented Ducasse. “The study will continue up to the five-year follow-up, and we are confident that the efficacy will be maintained, as demonstrated in other Luminor studies.”
The company have stated that the three-year findings add to the established and accumulating evidence base supporting the performance of Luminor in everyday clinical settings, complementing previous clinical evaluations, and further validating its role as a reliable therapy option in different type of peripheral artery disease thanks to the TransferTech nanotechnology.
